All Outputs (9)

Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study (2023)
Journal Article
Hamill, V., Wong, S., Benselin, J., Krajden, M., Hayes, P. C., Mutimer, D., …Innes, H. (2023). Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study. BMJ, 382, Article e074001. https://doi.org/10.1136/bmj-2022-074001

Objectives To quantify mortality rates for patients successfully treated for hepatitis C in the era of interferon-free, direct acting antivirals and compare these rates with those of the general population. Design Population based cohort study.... Read More about Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease (2023)
Journal Article
Nielsen, M. J., Dolman, G. E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J. I., …Guha, I. N. (2023). PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease. JHEP Reports, 5(6), Article 100743. https://doi.org/10.1016/j.jhepr.2023.100743

Background & Aims: Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation... Read More about PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.

Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK (2023)
Journal Article
Hamill, V., Gelson, W., MacDonald, D., Richardson, P., Ryder, S. D., Aldersley, M., …Innes, H. (2023). Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK. Liver International, 43(4), 917-927. https://doi.org/10.1111/liv.15528

Background: Previous studies show the uptake of biannual ultrasound (US) surveillance in patients with cirrhosis is suboptimal. Here, our goal was to understand in broader terms how surveillance is being delivered to cirrhosis patients with cured hep... Read More about Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK.

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study (2022)
Journal Article
Buch, S., Innes, H., Lutz, P. L., Nischalke, H. D., Marquardt, J. U., Fischer, J., …Stickel, F. (2022). Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study. Gut, https://doi.org/10.1136/gutjnl-2022-327196

Objective: Hepatocellular carcinoma (HCC) often develops in patients with alcohol-related cirrhosis at an annual risk of up to 2.5%. Some host genetic risk factors have been identified but do not account for the majority of the variance in occurrence... Read More about Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study.

Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis (2022)
Journal Article
Innes, H., Walker, A. J., Benselin, J., Grove, J. I., Pedergnana, V., Azim Ansari, M., …Guha, I. N. (2022). Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis. Clinical and Translational Gastroenterology, 13(3), Article e00462. https://doi.org/10.14309/ctg.0000000000000462

INTRODUCTION: Risk-stratifying patients with hepatitis C virus (HCV) cirrhosis according to medium-term prognosis will inform clinical decision-making. It is unclear which biomarkers/models are optimal for this purpose. We quantified the discriminati... Read More about Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis.

The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis (2021)
Journal Article
Innes, H., Nischalke, H. D., Guha, I. N., Weiss, K. H., Irving, W., Gotthardt, D., …Buch, S. (2022). The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 6(5), 1213-1226. https://doi.org/10.1002/hep4.1886

The host genetic background for hepatocellular carcinoma (HCC) is incompletely understood. We aimed to determine if four germline genetic polymorphisms, rs429358 in apolipoprotein E (APOE), rs2642438 in mitochondrial amidoxime reducing component 1 (M... Read More about The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis.

Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection (2021)
Journal Article
Innes, H., Jepsen, P., McDonald, S., Dillon, J., Hamill, V., Yeung, A., …Guha, I. N. (2021). Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. JHEP Reports, 3(6), Article 100384. https://doi.org/10.1016/j.jhepr.2021.100384

Background & Aims: Hepatocellular carcinoma (HCC) prediction models can inform clinical decisions about HCC screening provided their predictions are robust. We conducted an external validation of 6 HCC prediction models for UK patients with cirrhosis... Read More about Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection.

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis (2020)
Journal Article
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., …Hou, J. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 73(6), 1368-1378. https://doi.org/10.1016/j.jhep.2020.07.025

© 2020 European Association for the Study of the Liver Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HC... Read More about aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.

SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis (2018)
Journal Article
Athwal, V. S., Pritchett, J., Martin, K., Llewellyn, J., Scott, J., Harvey, E., …Hanley, K. P. (2018). SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. Scientific Reports, 8(1), Article 17905. https://doi.org/10.1038/s41598-018-36037-4

Extracellular matrix (ECM) deposition and resultant scar play a major role in the pathogenesis and progression of liver fibrosis. Identifying core regulators of ECM deposition may lead to urgently needed diagnostic and therapetic strategies for the d... Read More about SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis.